Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2013

01-03-2013 | Original Article

Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis

Authors: B. McGowan, M. C. Casey, C. Silke, B. Whelan, K. Bennett

Published in: Osteoporosis International | Issue 3/2013

Login to get access

Abstract

Summary

In Ireland, the absolute numbers of hospitalisations for all osteoporotic-type fractures including hip fractures increased between 2000 and 2009 along with the mean length of stay. The cost of hospitalisations for these fractures also increased between 2003 and 2008.

Introduction

The purposes of the study were to carry out a trend analyses of the total number of osteoporotic-type fractures in males and females aged 50 years and over in Ireland between 2000 and 2009 and to project the number of osteoporotic-type fractures in the Republic of Ireland expected by 2025.

Methods

Age- and gender-specific trends in the absolute numbers and direct age-standardised rates of hospitalisations for all osteoporotic-type fractures in men and women ≥50 years were analysed, along with the associated hospitalisation costs and length of stay using the Hospital In-Patient Enquiry system database. Future projections of absolute numbers of osteoporotic-type fractures in years 2015, 2020 and 2025 were computed based on the 2009 incidence rates applied to the projected populations.

Results

Between 2000 and 2009, the absolute numbers of all osteoporotic-type fractures increased by 12 % in females and by 15 % in males while the absolute numbers of hip fractures increased by 7 % in women and by 20 % in men. The age-specific rates for hip fractures decreased in all age groups with the exception of the 55–59-year age group which showed an increase of 4.1 % (p = 0.023) within the study period. The associated hospitalisation costs and length of stay increased. Assuming stable age-standardised incidence rates from 2009 over the next 20 years, the number of all types of osteoporotic-type fractures is projected to increase by 79 % and the number of hip fractures is expected to increase by 88 % by 2025.

Conclusions

Hospitalisations for osteoporotic-type fractures continued to increase in Ireland. Hip fractures increased by 7 % in women and 20 % in men.
Appendix
Available only for authorised users
Literature
1.
Anonymous (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650
2.
3.
Melton LJ 3rd, Kearns AE, Atkinson EJ et al (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694PubMedCrossRef
4.
Gehlbach SH, Avrunin JS, Puleo E (2007) Trends in hospital care for hip fractures. Osteoporos Int 18:585–591PubMedCrossRef
5.
Brauer CA, Coca-Perraillon M, Cutler DM et al (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579PubMedCrossRef
6.
Leslie WD, O’Donnell S, Jean S et al (2009) Trends in hip fracture rates in Canada. JAMA 302:883–889PubMedCrossRef
7.
8.
Orimo H, Yaegashi Y, Onoda T et al (2009) Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 4:71–77PubMedCrossRef
9.
Kannus P, Niemi S, Parkkari J et al (2006) Nationwide decline in incidence of hip fracture. J Bone Miner Res 21:1836–1838PubMedCrossRef
10.
Abrahamsen B, Vestergaard P (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. Osteoporos Int 21:373–380PubMedCrossRef
11.
12.
Chevalley T, Guilley E, Herrmann FR et al (2007) Incidence of hip fracture over a 10-year period (1991–2000): reversal of a secular trend. Bone 40:1284–1289PubMedCrossRef
13.
Guilley E, Chevalley T, Herrmann F et al (2008) Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int 19:1741–1747PubMedCrossRef
14.
Mann E, Icks A, Haastert B et al (2008) Hip fracture incidence in the elderly in Austria: an epidemiological study covering the years 1994–2006. BMC Geriatr 8:35PubMedCrossRef
15.
Hernandez JL, Olmos JM, Alonso MA et al (2006) Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos Int 17:464–470PubMedCrossRef
16.
Wildner M, Clark DE (2001) Hip fracture incidence in East and West Germany: reassessement ten years after unification. Osteoporos Int 12:136–139PubMedCrossRef
17.
Icks A, Haastert B, Wildner M et al (2008) Trend of hip fracture incidence in Germany 1995–2004: a population-based study. Osteoporos Int 19:1139–1145PubMedCrossRef
18.
Green C, Molony D, Fitzpatrick C, O’Rourke K (2010) Age-specific incidence of hip fracture in the elderly: a healthy decline. Surgeon 8(6):310–313PubMedCrossRef
19.
Dodds MK, Codd MB, Looney A, Mulhall KJ (2009) Incidence of hip fracture in the Republic of Ireland and future projections: a population-based study. Osteoporos Int 20:2105–2110PubMedCrossRef
20.
21.
22.
23.
Cooper C, Cole ZA, Holroyd CR et al (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedCrossRef
24.
Giversen IM (2006) Time trends of age-adjusted incidence rates of first hip fractures: a register-based study among older people in Viborg County, Denmark, 1987–1997. Osteoporos Int 17:552–564PubMedCrossRef
25.
Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1–12
26.
Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of post-menopausal osteoporosis. Calcif Tissue Int 71:103–111PubMedCrossRef
27.
Chestnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef
28.
Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654–661PubMedCrossRef
29.
Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42PubMedCrossRef
30.
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727–1736PubMedCrossRef
31.
Langley J, Samaranayaka A, Davie G, Campbell AJ (2011) Age, cohort and period effects on hip fracture incidence: analysis and predictions from New Zealand data 1974–2007. Osteoporos Int 22(1):105–111PubMedCrossRef
32.
McGowan B, Bennett K (2012) Adherence with antiosteoporosis medications: a primary–care study. Prescriber, 34–37
33.
Hulme PA, Krebs J, Ferguson SJ et al (2006) Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine (Phila Pa 1976) 31:1983–2001CrossRef
34.
Nikkel LE, Fox EJ, Black KP, Davis C, Andersen L, Holenbeak CS (2012) Impact of comorbidities on hospitalization costs following hip fracture. J Bone Joint Surg 94:9–17PubMedCrossRef
35.
36.
37.
38.
Chrischilles EA, Dashback EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM, Fracture Intervention Trial Research Group (2001) The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 12:654–660PubMedCrossRef
39.
Johnell O, Jonssen B, Jonssen L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef
40.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef
41.
Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year randomized, placebo-controlled trial. Arthris Rheum 58(6):1687–1695CrossRef
42.
Lundkvist J, Johnell O, Cooper C, Sykes D (2006) Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 17:201–211PubMedCrossRef
43.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Freedom Trial (2009) Denosumab for the prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 351(8):756–765CrossRef
44.
45.
46.
Metadata
Title
Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis
Authors
B. McGowan
M. C. Casey
C. Silke
B. Whelan
K. Bennett
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2032-8

Other articles of this Issue 3/2013

Osteoporosis International 3/2013 Go to the issue

Original Article

Vertebral fracture assessment scans enhance targeting of investigations and treatment within a fracture risk assessment pathway

Case Report

Alopecia associated with strontium ranelate use in a 62-year-old woman

Short Communication

Intact fibroblast growth factor 23 and fragments in plasma from Gambian children

Original Article

The effect of intravertebral heterogeneity in microstructure on vertebral strength and failure patterns

Original Article

Quality of fracture risk assessment in post-fracture care in Ontario, Canada

Original Article

Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis